Pacira Reports Strong Preliminary Q4 & Full-Year 2025 Revenue Growth, Announces Significant Share Repurchase

summarizeSummary

Pacira BioSciences reported preliminary unaudited Q4 and full-year 2025 revenues, highlighted by record-high EXPAREL sales and a substantial $50 million share repurchase, signaling strong operational performance and management confidence.

check_boxKey Events

• Preliminary Full-Year 2025 Revenue Growth

  Pacira reported preliminary unaudited total revenue of $726.4 million for the full-year ended December 31, 2025, an increase from $701.0 million in 2024.

• Record-High EXPAREL Sales in Q4 2025

  Preliminary unaudited EXPAREL net product sales reached $155.8 million in Q4 2025, up from $147.7 million in Q4 2024, driven by 7% volume growth and marking the strongest fourth quarter performance in three years.

• Significant Share Repurchase Program

  The company repurchased 2.0 million shares of its common stock for $50.0 million during the fourth quarter of 2025, with $150.0 million remaining on its current authorization.

• Other Product Sales Performance

  Preliminary unaudited Q4 2025 ZILRETTA net product sales were $33.0 million (vs. $33.1 million in 2024), and iovera° net product sales were $7.0 million (vs. $6.5 million in 2024).

auto_awesomeAnalysis

Pacira BioSciences reported robust preliminary unaudited revenues for Q4 and full-year 2025, driven by record-high EXPAREL sales with 7% volume growth in the fourth quarter. This performance, marking the strongest Q4 in three years for EXPAREL, indicates solid execution on commercial investments and positive momentum for the company's core product. Additionally, the company's repurchase of $50 million in common stock during Q4 demonstrates strong management confidence and a commitment to returning value to shareholders, representing a substantial capital allocation relative to the company's market capitalization. Investors should view these results as a positive indicator of operational strength and financial health.